Literature DB >> 18987928

Intrahepatic dissemination of hepatocellular carcinoma after local ablation therapy.

Toshiro Masuda1, Toru Beppu, Takatoshi Ishiko, Kei Horino, Yoshifumi Baba, Takao Mizumoto, Hiromitsu Hayashi, Hirohisa Okabe, Hasita Horlad, Koichi Doi, Kazutoshi Okabe, Hiroshi Takamori, Masahiko Hirota, Ken-ichi Iyama, Hideo Baba.   

Abstract

BACKGROUND/
PURPOSE: We aimed to clarify the histological features of and risk factors for intrahepatic dissemination after local ablation therapy (LAT) for hepatocellular carcinoma (HCC).
METHODS: Between April 1992 and December 2005, 192 HCC patients underwent hepatic resection at our department, among whom were 17 patients who had local recurrences after LAT. Eight of these 17 patients had intrahepatic dissemination. The clinical and histological characteristics of these 8 surgically treated patients with intrahepatic dissemination were investigated.
RESULTS: Histologically, numerous intrahepatic metastases were observed, mainly in the same section as the treated tumor, together with main or sectional portal vein tumor thrombi. Before the ablation therapy, the average tumor diameter was 2.1 cm, and 62.5% of the tumors were adjacent to the main or sectional portal vein. In terms of therapeutic factors, 25% of the patients had a prior needle biopsy and 62.5% had insufficient safety margins.
CONCLUSIONS: LAT for HCCs (even those less than 3 cm in diameter) adjacent less than 5 mm to the main or sectional portal vein possibly promotes intrahepatic dissemination.

Entities:  

Mesh:

Year:  2008        PMID: 18987928     DOI: 10.1007/s00534-007-1288-4

Source DB:  PubMed          Journal:  J Hepatobiliary Pancreat Surg        ISSN: 0944-1166


  17 in total

1.  Adjuvant hepatic arterial infusion chemotherapy after hepatic resection of hepatocellular carcinoma with macroscopic vascular invasion.

Authors:  Hidetoshi Nitta; Toru Beppu; Katsunori Imai; Hiromitsu Hayashi; Akira Chikamoto; Hideo Baba
Journal:  World J Surg       Date:  2013-05       Impact factor: 3.352

2.  Opposing Roles of the Forkhead Box Factors FoxM1 and FoxA2 in Liver Cancer.

Authors:  Vaibhav Chand; Akshay Pandey; Dragana Kopanja; Grace Guzman; Pradip Raychaudhuri
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

3.  FoxM1: a master regulator of tumor metastasis.

Authors:  Pradip Raychaudhuri; Hyun Jung Park
Journal:  Cancer Res       Date:  2011-06-28       Impact factor: 12.701

Review 4.  Application of Radiotherapeutic Strategies in the BCLC-Defined Stages of Hepatocellular Carcinoma.

Authors:  Cha Jihye; Seong Jinsil
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 5.  Role of hepatectomy for recurrent or initially unresectable hepatocellular carcinoma.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Tomoo Kosuge
Journal:  World J Hepatol       Date:  2014-12-27

6.  Radiofrequency hyperthermia-enhanced herpes simplex virus-thymidine kinase/ganciclovir direct intratumoral gene therapy of hepatocellular carcinoma.

Authors:  Jianfeng Wang; Yaoping Shi; Zhibin Bai; Yonggang Li; Longhua Qiu; Guy Johnson; Feng Zhang; Xiaoming Yang
Journal:  Int J Hyperthermia       Date:  2016-09-20       Impact factor: 3.914

Review 7.  Challenge and hope in radiotherapy of hepatocellular carcinoma.

Authors:  Jinsil Seong
Journal:  Yonsei Med J       Date:  2009-10-20       Impact factor: 2.759

8.  Pre-treatment double- or triple-positive tumor markers are predictive of a poor outcome for patients undergoing radiofrequency ablation for hepatocellular carcinoma.

Authors:  Hidetoshi Nitta; Shigeki Nakagawa; Takayoshi Kaida; Kota Arima; Takaaki Higashi; Katsunobu Taki; Hirohisa Okabe; Hiromitsu Hayashi; Daisuke Hashimoto; Akira Chikamoto; Takatoshi Ishiko; Toru Beppu; Hideo Baba
Journal:  Surg Today       Date:  2016-08-22       Impact factor: 2.549

9.  The arterial tumor enhancement pattern on contrast-enhanced computed tomography is associated with primary cancer death after radiofrequency ablation for small hepatocellular carcinoma.

Authors:  Ryo Shimizu; Hideyuki Tamai; Yoshiyuki Mori; Naoki Shingaki; Shuya Maeshima; Junya Nuta; Yoshimasa Maeda; Kosaku Moribata; Yosuke Muraki; Hisanobu Deguchi; Izumi Inoue; Takao Maekita; Mikitaka Iguchi; Jun Kato; Masao Ichinose
Journal:  Hepatol Int       Date:  2015-11-03       Impact factor: 6.047

Review 10.  Oncological benefits of portal vein embolization for patients with hepatocellular carcinoma.

Authors:  Toru Beppu; Kensuke Yamamura; Hirohisa Okabe; Katsunori Imai; Hiromitsu Hayashi
Journal:  Ann Gastroenterol Surg       Date:  2020-12-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.